The technology appraisal specifies that dimethyl fumarate should not be used in patients with highly active or rapidly-evolving severe RRMS and that the manufacturer must provide the drug with the discount agreed in the patient access scheme. RRMS is normally defined as two clinically significant relapses in the previous two years.
Click to search or browse MIMS
The most up-to-date drug information at your fingertips.
- Get the prescribing support you need.
- Register today for full access to the MIMS database, plus tables and guideline summaries, new and deleted products and consultation tools.
Read the latest issue online exclusively on MIMS Learning.
Access the full drug database and quick-reference tables on the go